This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top
by Zacks Equity Research
Seattle Genetics (SGEN) first-quarter earnings miss estimates while sales beat the same.
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down
by Zacks Equity Research
Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
by Zacks Equity Research
Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.
Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
by Zacks Equity Research
Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.
What's in Store for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q1 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Bristol-Myers' Opdivo Gets Priority Review for Lung Cancer
by Zacks Equity Research
The FDA accepts Bristol-Myers Squibb's (BMY) supplemental Biologics License Application and grants priority review for the label expansion of Opdivo to treat patients with small cell lung cancer.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
Roche Hemophilia Drug Gets Breakthrough Therapy Designation
by Zacks Equity Research
The FDA grants Breakthrough Therapy Designation to Roche's (RHHBY) Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
We expect investors to focus on the performance of newly launched drugs when Novartis (NVS) reports its first-quarter results.
Celldex's Phase II Breast Cancer Study Fails, Shares Plunge
by Zacks Equity Research
Celldex Therapeutics' (CLDX) glembatumumab vedotin fails to meet primary endpoint in phase IIb METRIC study in metastatic breast cancer.
Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.
Nektar Starts Phase I/II Combo for Advanced Solid Tumors
by Zacks Equity Research
Nektar (NKTR) initiates dosing in a phase I/II study, evaluating the combination of its two novel immuno-oncology agents, NKTR-262 and NKTR-214, on patients with advanced solid tumors.
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
by Zacks Equity Research
Mylan (MYL) has inked a deal with Israel based Mapi Pharma to acquire its multiple sclerosis candidate.
Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
by Zacks Equity Research
Pfizer's (PFE) regulatory application for dacomitinib gets accepted in the United States under priority review for non-small cell lung cancer. The EU also accepts the filing for the same indication.
Novartis Announces Data on Cardiovascular Drug Entresto
by Zacks Equity Research
Novartis AG (NVS) announces encouraging results from the PARADIGM-HF trial on cardiovascular drug Entresto in JAMA Cardiology wherein it was observed Entresto significantly improved seven out of 10 types of physical and social activities at eight months.
3 Emerging Technologies Set to Transform the Pharma World
by Kinjel Shah
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.
Celgene (CELG) President and COO to Step Down: What's Ahead?
by Zacks Equity Research
Celgene's (CELG) president and chief operating officer, Scott A. Smith, has decided to step down from his position with immediate effect further adding to the company's woes.
Fast Pipeline Progress Pushes ImmunoGen Above 150% in a Year
by Zacks Equity Research
ImmunoGen's (IMGN) shares shoot up more than 150% in a year's time on rapid pipeline progress, positive study data and strategic collaborations.
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
by Zacks Equity Research
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Celgene (CELG) Up on Deal With bluebird For CAR-T Candidate
by Zacks Equity Research
Celgene's (CELG) stock was up by 3% after the company announced a co-promotion agreement with bluebird bio for one of its leading CAR-T candidates.
FDA Nods for Bristol-Myers' Colorectal Cancer Combo Therapy
by Zacks Equity Research
Bristol-Myers' (BMY) filing for Opdivo in combination with Yervoy gains acceptance from the FDA for treating metastatic colorectal cancer. A response is expected in July, 2018.
Celgene Loses 17.8% in 3 Months: Time to Reshuffle Portfolio?
by Zacks Equity Research
Things have not been going Celgene's (CELG) way as the company has suffered a series of setbacks. The stock has lost 17.8% in the last three months.
Roche's Tecentriq Combo Study Meets Co-Primary Endpoint
by Zacks Equity Research
Roche's (RHHBY) phase III study, evaluating a combination of Tecentriq and Avastin plus carboplatin and paclitaxel for first line treatment of advanced lung cancer met its co-primary endpoint of overall survival.
Exelixis Cabometyx Gets Positive CHMP Opinion in Europe
by Zacks Equity Research
Exelixis' European partner, Ipsen, obtains positive opinion from the CHMP for the use of Cabometyx in the first-line treatment of advanced renal cell carcinoma.